TACE plus Immunotherapy for Advanced Liver Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your liver cancer must be in an advanced stage (Stage C or advanced Stage B) and not treatable with surgery or local treatments.
- You must not have received any prior treatment for your liver cancer before.
- You must be in good enough health to undergo treatment (ECOG score 0–1).
- Your liver, kidney, and blood cell counts must be within certain acceptable ranges.
- You must be willing to provide a tumor tissue sample and blood samples.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining TACE (a liver-targeted chemo procedure) with two medicines—an immune “checkpoint” drug and a blood-vessel blocking drug—can control unresectable hepatocellular carcinoma. It’s designed for people who can’t have surgery or curative ablation, and who still have reasonably strong liver and overall health.
This study tests a combination of two treatments for advanced liver cancer (hepatocellular carcinoma): a bile acid supplement called tauroursodeoxycholic acid plus an immunotherapy drug (a PD-1/PD-L1 inhibitor) that helps your immune system fight the cancer. The goal is to see if this combination is safe and effective in people who have not yet had any whole-body cancer treatment.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This trial studies a combination treatment for hepatocellular carcinoma (liver cancer) that cannot be removed with surgery or transplant. It adds cabozantinib and immunotherapy (ipilimumab plus nivolumab) to TACE, a procedure that delivers medicine directly to the liver tumor area.
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
This trial tests a combination of an immunotherapy drug (QL1706) and a liver-directed procedure (TACE) before and after surgery for people with liver cancer that is larger or more advanced than the usual transplant criteria. The goal is to see if this approach can help shrink the tumor and improve outcomes.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.